Aligos Therapeutics (NASDAQ:ALGS) Trading Down 6% – Time to Sell?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) fell 6% during mid-day trading on Wednesday . The stock traded as low as $6.81 and last traded at $7.07. 52,875 shares traded hands during trading, a decline of 33% from the average session volume of 78,377 shares. The stock had previously closed at $7.52.

Analysts Set New Price Targets

ALGS has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Wednesday, January 21st. Wall Street Zen lowered Aligos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, UBS Group began coverage on Aligos Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price target on the stock. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aligos Therapeutics currently has a consensus rating of “Hold” and an average target price of $35.00.

Aligos Therapeutics Stock Down 6.0%

The company has a market capitalization of $43.48 million, a PE ratio of -0.36 and a beta of 2.66. The stock’s fifty day moving average price is $9.46 and its two-hundred day moving average price is $9.26.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, November 6th. The company reported ($3.04) EPS for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.95). The business had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.50 million. Aligos Therapeutics had a negative net margin of 3,267.65% and a negative return on equity of 39.35%. On average, equities research analysts forecast that Aligos Therapeutics, Inc. will post -10.36 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ALGS. Sio Capital Management LLC raised its holdings in Aligos Therapeutics by 85.9% in the 2nd quarter. Sio Capital Management LLC now owns 335,937 shares of the company’s stock worth $2,422,000 after purchasing an additional 155,217 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Aligos Therapeutics during the first quarter valued at about $2,602,000. Readystate Asset Management LP raised its stake in Aligos Therapeutics by 48.5% in the third quarter. Readystate Asset Management LP now owns 203,113 shares of the company’s stock worth $1,991,000 after buying an additional 66,331 shares in the last quarter. Vanguard Group Inc. raised its stake in Aligos Therapeutics by 22.8% in the third quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after buying an additional 31,913 shares in the last quarter. Finally, Two Sigma Investments LP lifted its holdings in Aligos Therapeutics by 223.0% in the third quarter. Two Sigma Investments LP now owns 38,995 shares of the company’s stock worth $382,000 after buying an additional 26,922 shares during the period. 60.43% of the stock is owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.